ClinicalTrials.gov
public full text
Public Domain
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients. The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine, a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- D-serine Monotherapy for Schizophrenia#884301
- Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis#911998
- A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients#827155
- N-methylglycine (Sarcosine) Treatment for Depression#914050
- Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism#980298
Record · ID 981342
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive